"The Medicare Drug Coverage Preservation Act of 2000," a bill that would guarantee Medicare coverage of certain injectable drugs, was introduced in the House by Health and Environment Subcommittee Chairman Michael Bilirakis (R-FL).
"The Medicare Drug Coverage Preservation Act of 2000," a bill that would guarantee Medicare coverage of certain injectable drugs, was introduced in the House by Health and Environment Subcommittee Chairman Michael Bilirakis (R-FL).
The bill ensures that Medicare beneficiaries who receive life-saving injectable drugs and biologicals would continue to have access to those therapies consistent with federal law. The bill continues a drug coverage policy that has been in effect since the establishment of Medicare 35 years ago by ensuring that patients, who cannot self-administer injectable drugs continue to get those drugs administered by their physicians and covered under the Medicare program.
The legislation reverses a 1997 HCFA directive, which had the effect of limiting coverage for injectable drugs for certain Medicare beneficiaries. Prior to August 1997, Medicare generally covered injectable drugs and biologics when administered in a physician's office. In August 1997, HCFA issued a memorandum to Medicare carriers that removed significant discretion in determining which patients were able to self-administer drugs and which patients needed the aid of a physician to administer injectables.
"I was shocked when HCFA terminated coverage of self-injectable drugs in August 1997," said Rep. Tom Bliley (R-VA), an original co-sponsor of the bill. "It is alarming when the federal government turns Medicare coverage on and off like a light switch. One minute, certain medicines are covered, and one minute they're not."
Another bill, "The Access to Innovation for Medicare Patients Act of 1999" introduced by Rep. Jennifer Dunn (R-WA), proposes to extend Medicare Part B to include any self-injected biologic that could substitute for a currently covered clinician-administered drug or biological.
The Lewin Group, a Falls Church, VA-based consulting firm, estimated that the Dunn bill would save Medicare $2 million in treatment costs for conditions covered by the bill. "We are dealing here with some of society's most debilitated patients," said Lewin Group study director Catherine Harrington. "These patients find it hard to leave home to travel long distances to specialists or clinics. Coverage of self-injected biologicals would eliminate unnecessary office visits, infusion charges and the staff time associated with infusing products." PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.